Short Interest in Celularity Inc. (NASDAQ:CELU) Grows By 50.0%

Celularity Inc. (NASDAQ:CELU) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,560,000 shares, a growth of 50.0% from the February 28th total of 1,040,000 shares. Based on an average daily volume of 159,900 shares, the short-interest ratio is currently 9.8 days. Approximately 11.9% of the shares of the stock are sold short.

Celularity Stock Performance

CELU opened at $1.77 on Friday. The firm’s fifty day moving average is $1.84 and its 200 day moving average is $2.22. Celularity has a fifty-two week low of $1.00 and a fifty-two week high of $5.69.

Hedge Funds Weigh In On Celularity

Several large investors have recently made changes to their positions in CELU. C V Starr & Co. Inc. bought a new stake in Celularity during the 4th quarter valued at approximately $1,589,000. Two Sigma Investments LP bought a new stake in shares of Celularity during the fourth quarter valued at approximately $93,000. Biltmore Family Office LLC bought a new stake in shares of Celularity during the fourth quarter valued at approximately $73,000. Finally, Keynote Financial Services LLC lifted its holdings in shares of Celularity by 90.1% in the fourth quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after buying an additional 11,863 shares in the last quarter. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.